Abstract
Clinical effects of aztreonam (AZT), a monobactam antibiotic, on perinatal infections were studied with the following results:
1. Efficacy rate of AZT in the clinical application to 12 cases of perinatal infections via 2-4g/day drip infusion (total dosage 8, -24 g) was 91.7% (11/12). Breakdown of the effects according to diseases were “excellent” for mastitis (n = 3), pyelonephritis (n =1) and urinary tract infection (n=1), and “good” for a total of 6 cases, i.e, amnionitis (n=2), amniotic fluid infections (n=3) and external genital infection (n=1).
2. Results of bacteriological studies were “eradicated” (n=1), “replaced” (n=4), “appeared” (n=2) and “unknown” (n=5). MIC values of AZT (106 cells/ml) were in a range of25->100 μg/ml in 1 case of cervicitis (complicated with amnionitis) in the 13th week of pregnancy where AZT was found noneffective.
3. Neither subjective nor objective side effects nor abnormal clinical values were observed during the treatment with AZT.
